Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 143Myelodysplastic Syndromes 53Leukemia 24Leukemia, Myelomonocytic, Chronic 21Recurrence 12Myeloproliferative Disorders 7Leukemia, Biphenotypic, Acute 7Carcinoma, Non-Small-Cell Lung 7Lymphoma, T-Cell, Peripheral 6Leukemia, Monocytic, Acute 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm, Residual 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myelomonocytic, Acute 5Anemia, Refractory, with Excess of Blasts 5Neoplasms 4Leukemia, Erythroblastic, Acute 4Congenital Abnormalities 4Prostatic Neoplasms 3Primary Myelofibrosis 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Pancreatic Neoplasms 2

Interventions

Carboplatin 79pembrolizumab 64Paclitaxel 64Cyclophosphamide 47Capecitabine 34Doxorubicin 31Taxes 28130-nm albumin-bound paclitaxel 28Albumin-Bound Paclitaxel 27Gemcitabine 20atezolizumab 18Epirubicin 18Cisplatin 18Bevacizumab 18olaparib 17sacituzumab govitecan 15Docetaxel 15eribulin 14toripalimab 13durvalumab 13camrelizumab 13Drug Therapy 12apatinib 9Trastuzumab 9Radiotherapy 9Specimen Handling 8Magnetic Resonance Spectroscopy 8Biopsy 8tislelizumab 7talazoparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Triple Negative Breast Neoplasms × Azacitidine × Clear all
NCT01349959 2025-04-27

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
58 enrolled 16 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡